comparemela.com
Home
Live Updates
Dr Drilon on the Potential Benefit of Taletrectinib in ROS1+ NSCLC : comparemela.com
Dr Drilon on the Potential Benefit of Taletrectinib in ROS1+ NSCLC
Alexander Drilon, MD, discusses the potential benefit of taletrectinib in patients with ROS1-positive non–small cell lung cancer.
Related Keywords
China
,
Alexander Drilon
,
Repotrectinib Augtyro
,
Memorial Sloan Kettering Cancer Center
,
Advances In Precision Medicine Lung Cancer
,
Onclive Tv
,
Lung Cancer
,
Publications
,
comparemela.com © 2020. All Rights Reserved.